Brokerages expect Perrigo Company PLC (NYSE:PRGO) to report $1.02 earnings per share for the current fiscal quarter, according to Zacks. Eleven analysts have made estimates for Perrigo’s earnings. The highest EPS estimate is $1.23 and the lowest is $0.87. Perrigo posted earnings of $1.28 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 20.3%. The firm is scheduled to issue its next earnings report on Thursday, March 7th.
On average, analysts expect that Perrigo will report full-year earnings of $4.57 per share for the current financial year, with EPS estimates ranging from $4.40 to $4.83. For the next year, analysts expect that the business will post earnings of $4.67 per share, with EPS estimates ranging from $4.03 to $5.14. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Perrigo.
Perrigo (NYSE:PRGO) last released its earnings results on Thursday, November 8th. The company reported $1.09 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.04. The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Perrigo had a return on equity of 11.32% and a net margin of 2.54%. The business’s revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.39 EPS.
PRGO has been the subject of several research analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $107.00 target price on shares of Perrigo in a research note on Monday, October 8th. Canaccord Genuity set a $90.00 target price on Perrigo and gave the company a “buy” rating in a research note on Friday, August 17th. Jefferies Financial Group reiterated a “hold” rating and set a $73.00 target price on shares of Perrigo in a research note on Friday, August 10th. Royal Bank of Canada reduced their target price on Perrigo from $89.00 to $67.00 and set a “hold” rating for the company in a research note on Friday, August 10th. Finally, Stifel Nicolaus reduced their target price on Perrigo from $92.00 to $87.00 and set a “hold” rating for the company in a research note on Friday, August 10th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $82.73.
Shares of Perrigo stock traded down $0.22 on Friday, hitting $62.62. 1,888,402 shares of the company’s stock traded hands, compared to its average volume of 1,284,054. The stock has a market cap of $8.54 billion, a P/E ratio of 12.71, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58. The company has a current ratio of 1.85, a quick ratio of 1.26 and a debt-to-equity ratio of 0.54. Perrigo has a 52-week low of $59.88 and a 52-week high of $95.93.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 18th. Investors of record on Friday, November 30th will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Thursday, November 29th. Perrigo’s dividend payout ratio (DPR) is presently 15.42%.
In other news, CEO Murray S. Kessler acquired 15,683 shares of Perrigo stock in a transaction that occurred on Friday, November 9th. The shares were purchased at an average cost of $63.79 per share, for a total transaction of $1,000,418.57. Following the completion of the purchase, the chief executive officer now directly owns 13,416 shares of the company’s stock, valued at approximately $855,806.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Svend Andersen acquired 3,900 shares of Perrigo stock in a transaction that occurred on Friday, November 9th. The shares were purchased at an average price of $63.01 per share, for a total transaction of $245,739.00. The disclosure for this purchase can be found here. Insiders have purchased 25,783 shares of company stock worth $1,646,976 over the last 90 days. 6.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of PRGO. Piedmont Investment Advisors LLC bought a new stake in Perrigo in the second quarter valued at $110,000. NuWave Investment Management LLC lifted its stake in Perrigo by 17,377.8% in the third quarter. NuWave Investment Management LLC now owns 1,573 shares of the company’s stock valued at $111,000 after buying an additional 1,564 shares during the last quarter. Dupont Capital Management Corp lifted its stake in Perrigo by 63.8% in the second quarter. Dupont Capital Management Corp now owns 1,705 shares of the company’s stock valued at $124,000 after buying an additional 664 shares during the last quarter. Rehmann Capital Advisory Group lifted its stake in Perrigo by 8,014.9% in the third quarter. Rehmann Capital Advisory Group now owns 14,120 shares of the company’s stock valued at $199,000 after buying an additional 13,946 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in Perrigo in the first quarter valued at $205,000. Institutional investors own 87.50% of the company’s stock.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Read More: Yield Curve
Get a free copy of the Zacks research report on Perrigo (PRGO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.